PSMA PET scans enable precise detection of prostate cancer even in its earliest stages, improving diagnostic accuracy and ...

Telix Pharma’s prostate cancer PET1 imaging agent, Illuccix receives European marketing approval: Melbourne, Australia Saturday, January 18, 2025, 10:00 Hrs [IST] Telix Pharmace ...

In morning trade on Friday, the ASX 200 healthcare stock is up 4.5% to a record high of $27.00. Get the latest from The ...

MELBOURNE, Australia and LIÈGE, Belgium, Jan. 16, 2025 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Nasdaq: TLX, Telix, the Company) today announces that it has received a positive ...

Telix Pharmaceuticals Limited today announces that it has received a positive decision on the Marketing Authorization ...

PSMA-PET/CT findings were positive in 84% of the patients. PSMA-PET/CT detected distant metastatic disease in 46% of patients, including 34% of patients after RP, 56% after definitive RT, and 60% ...

Malaysia, meanwhile, is emerging as a prominent leader in adopting advanced prostate cancer treatments and diagnostics, including Prostate-Specific Membrane Antigen (PSMA) PET scans and Stereotactic ...

Telix is in a strong financial position with net cash of AUD 119 million as of June 2024. We forecast free cash flow averaging 82% of net income over the next 10 years, and in the absence of major ...

New consensus recommendations address implementation of novel treatments and imaging techniques for advanced and ...

This advanced imaging technology plays a critical role in redefining how prostate cancer is staged. PSMA-PET imaging uses tiny amounts of radioactive “tracers,” called radiotracers, that binds to ...

PET/CT imaging identified metastatic prostate cancer in almost half of high-risk cases missed by conventional imaging, a ...

Prostate-specific membrane antigen-positron emission tomography (PSMA-PET) frequently detects metastatic disease missed by conventional imaging, investigators report.